Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc. | Eprenetapopt (APR-246) and VIDAZA (azacitidine) | TP53 mutant Myelodysplastic syndromes (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Trial Completed | Eprenetapopt intravenous VIDAZA subcutaneous or intravenous | Oncology |
| Aquestive Therapeutics Inc. | AQST-108 (epinephrine) Topical Gel | Alopecia areata (AA) | Phase 2a | Trial Planned | Sublingual | Immunology |
| Arbutus Biopharma Corporation | Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I) | Hepatitis B (HBV) | Phase 2a | Data Released | Subcutaneous | Antiviral |
| Arbutus Biopharma Corporation | Imdusiran (AB-729 w/ NA therapy and Peginterferon alfa-2a) - (IM-PROVE II) | Chronic Hepatitis B | Phase 2a | Trial Discontinued | Subcutaneous | Antiviral |
| Arbutus Biopharma Corporation | AB-101 (Oral PD-L1 Inhibitor) | Hepatitis B, healthy volunteers | Phase 3 | Ongoing | Oral | N/A |
| Arbutus Biopharma Corporation | AB-729, Vebicorvir (ABI-H0731) and nucleos(t)ide analogue (NA) | Hepatitis B virus (HBV) | Phase 2a | Trial Discontinued | AB-729 subcutaneous Vebicorvir oral nucleos(t)ide analogue oral | Antiviral |
| Arcellx Inc. | CART-ddBCMA - (iMMagine-1) | Multiple Myeloma | Phase 2 | Data Released | Intravenous | Oncology |
| Arcellx Inc. | CART-ddBCMA - (iMMagine-1) | Multiple Myeloma | Phase 2 | Data Released | Intravenous | Oncology |
